Market Performance - The Hong Kong stock market showed a weak performance on May 13, with major indices declining, particularly the Hang Seng Tech Index which fell by 3.26% [1][2] - The Hang Seng Index and the China Enterprises Index decreased by 1.87% and 2.02% respectively, ending an eight-day rally for the Hang Seng Index [1][2] Sector Performance - Major technology stocks experienced significant declines, with Meituan and Kuaishou dropping over 4%, while Alibaba and Xiaomi fell more than 3% [4][5] - Apple-related stocks, automotive stocks, and semiconductor stocks also saw notable declines, with some Apple-related stocks dropping over 7% [5][6] - The semiconductor sector faced losses, with companies like Hua Hong Semiconductor and SMIC falling over 4% [7][8] Short Selling and Market Sentiment - There was a substantial increase in short selling of major tech companies from May 8 to May 12, raising concerns about the sustainability of the market rebound [4] - The market sentiment shifted towards increased bearishness following positive signals in US-China trade relations [4] Gold and Biopharmaceuticals - Gold stocks gained traction, with significant increases in companies like Tongguan Gold, which rose over 15% [9][10] - Biopharmaceutical stocks rebounded, with companies like Junshi Biosciences and Innovent Biologics seeing gains of over 4% [9] Banking Sector - The banking sector saw gains, with banks like Chongqing Bank and Jiangxi Bank rising over 4% following a 0.5% reserve requirement ratio cut announced by the People's Bank of China [11] Investment Outlook - Nomura Securities upgraded its rating on Chinese stocks to "tactical overweight" post US-China trade negotiations, indicating a shift in investment strategy [13] - Citigroup raised its year-end target for the Hang Seng Index by 2% to 25,000 points, projecting it could reach 26,000 by mid-2026 [13]

Market Overview - The A-share market showed mixed performance on May 13, with the Shanghai Composite Index rising by 0.17%, while the Shenzhen Component and ChiNext Index fell by 0.13% and 0.12% respectively [1] Active Sectors - The port and shipping sector, closely related to foreign trade, saw significant gains, with stocks like Ningbo Shipping and Ningbo Ocean reaching their daily limit [2] - The banking sector experienced a positive trend, with all bank stocks rising, including historical highs for Shanghai Pudong Development Bank, Shanghai Bank, Chengdu Bank, and Jiangsu Bank [2] - The photovoltaic industry chain, including photovoltaic equipment, BC batteries, and POE films, also saw an increase. Guojin Securities forecasts a sustained growth rate of 10% to 15% for new photovoltaic installations by 2025, with diverse regional distribution expected to drive demand [3] - The consumer sector, particularly in beauty and personal care, led the gains, with stocks like Jinbo Biological and Runben Co. reaching historical highs. Analysts noted the rise of the "beauty economy" and self-care trends driving consumer purchases in skincare and cosmetics [4] - The chemical sector, including epoxy propane and dyes, experienced an uptick, with popular stocks like Zhongyida and Hongqiang Co. hitting their daily limit [5] - The pharmaceutical sector, particularly in medical services and gene sequencing, also saw growth. OpenAI announced a new testing evaluation set for healthcare AI systems, which may enhance capabilities in the medical field [6]

（原标题：港股通创新药ETF工银、港股通创新药ETF、恒生医疗ETF、医疗ETF上涨，机构看好医药赛道） 上证指数收涨0.17%，创业板指跌0.12%。海运港口股掀涨停潮，银行、医药涨幅居前。 ETF方面，港股通创新药ETF工银、汇添富港股通创新药ETF、景顺长城港股创新药50ETF、富国恒生医疗ETF、国泰创新药沪深港ETF、医疗ETF 易方达、华夏医疗器械ETF、华宝医疗ETF、嘉实恒生医疗指数ETF、博时恒生医疗ETF、广发港股创新药ETF涨超1.5%。 资金净流入部分医药主题ETF。其中，截至5月12日，汇添富港股通创新药ETF、富国恒生医疗ETF、华宝医疗ETF、银华港股创新药ETF、银华创 新药ETF、天弘生物医药ETF、广发港股创新药ETF、医疗ETF易方达年内净流入额分别为21.99亿元、13.27亿元、12.29亿元、9.45亿元、6.94亿 元、4.75亿元、4.5亿元、 2.28亿元。 消息面上，中美经贸高层会谈联合声明发布，双方同意大幅降低双边关税水平，美方取消共计91%的加征关税，中方相应取消91%的反制关税； 美方暂停实施24%的"对等关税"，中方也相应暂停实施24%的反制关税。 ...

智通财经5月13日电，午后贝瑞基因涨停，华大基因涨超15%，迪安诊断、安必平、嘉和美康、美年健 康、润达医疗等涨幅靠前。消息面上，OpenAI宣布推出了一个专门面向医疗大模型的测试评估集 —— HealthBench 并开源，旨在更好地衡量 AI 系统在医疗健康领域能力，为进一步推动AI医疗技术的发展 和应用做出重要贡献。 AI医疗概念震荡走强 贝瑞基因涨停 ...

5月份，增量政策可能不多，但储备政策不少，政策定力仍然很强，目标是应对关税的冲击。因此，市 场在度过业绩风险后仍然会关注科技成长主题。内需相关板块仍会是国内政策的首要着力点，低利率环 境下业绩稳定的高股息板块仍有配置价值。除此以外，在可能出现的关税缓和过程中，那些品牌力强、 定价能力强、替代难度大的公司有望迎来估值的修复。 谭小兵：看好有边际变化的成长股 4月份市场呈现V字形走势，内需与红利好于成长股。展望5月份，进入业绩真空期，市场对指数填补之 后能否继续上攻还是存在分歧，个人相对还是偏乐观：一方面是国内政策会逐步兑现；另一方面中美谈 判或拉开序幕，这有利于修复市场的风险偏好。方向上看好有边际变化的成长股。 回顾4月，美国"对等关税"来袭，全球市场剧烈波动，就中国资产来看，月内A股和港股主要指数收 跌。进入5月，尽管外部不确定性因素依然存在，但中美关税谈判窗口有望来临，国内一揽子增量政策 也在加速落地，为国内股市稳定发展带来有力支撑。 展望后市，市场将会如何演绎？哪些投资机会值得关注？一起来看看长城基金权益基金经理们的观点吧 ~ 杨建华：持续关注关税政策 展望5月，关税政策及中美贸易谈判仍将会成为左右市场的 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is focusing on innovation, with a positive trend in innovative drugs supported by policies and increasing global competitiveness [2] - The Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine Index has shown a 1.27% increase, indicating a recovery in the biotech sector [1] - The ETF tracking the Biomedicine Index has seen a 1.17% rise, with significant trading volume exceeding 8.12 million yuan, reflecting investor interest [1] Group 2 - The pharmaceutical industry is expected to see a recovery in demand by 2025, particularly in the consumer healthcare sector, driven by improving economic fundamentals [2] - The medical device sector is also anticipated to improve by 2025, indicating a broader recovery in the healthcare industry [2] - AI in healthcare is highlighted as a significant technological trend that could bring changes to the pharmaceutical industry [2] Group 3 - The pharmaceutical index has stabilized after a period of decline since 2021, with signs of recovery beginning in Q4 2024 [2] - The ongoing innovation in the pharmaceutical sector, along with favorable drug procurement policies, is expected to drive a new growth cycle [2] - The aging population and unmet clinical needs are contributing to long-term growth trends in the pharmaceutical industry [2]

截至2025年5月13日 09:39，恒生医疗保健指数(HSHCI)强势上涨1.38%，成分股百济神州(06160)上涨5.16%，医脉通(02192)上涨5.15%，乐普生物-B(02157)上 涨4.67%，信达生物(01801)，翰森制药(03692)等个股跟涨。恒生医疗ETF(513060)上涨1.72%，最新价报0.47元。流动性方面，恒生医疗ETF盘中换手 3.08%，成交3.05亿元。拉长时间看，截至5月12日，恒生医疗ETF近1月日均成交13.50亿元，排名可比基金第一。 德邦证券指出，AI的发展带动AI医疗的全面普及，大量医疗企业接入DS、华为等AI模型，开始摸索AI在医疗的应用。我们认为，1）拥有大量底层病人数据 的企业将有很大应用落地空间，2）拥有医保数据的企业有望深入应用AI，3）AI制药继续升级，建议关注此类公司。此外，积极关注1）创新药及其产业链 的技术革新与BD潜力；2）有业绩，基本面出现拐点的企业。 西南证券表示，2025年2月，国产大模型DeepSeek-R1全面开源与多领域适配，AI医疗迈入技术融合与行业重构的新阶段，DeepSeek的多模型协同能力成为 行业新范式。这种" ...

Policy Developments - Heilongjiang Province has initiated a joint action among eight departments to regulate illegal medical advertisements, particularly targeting "miracle doctor" ads that mislead consumers by using false credentials or endorsements [2] Drug and Device Approvals - Merck announced the launch of its new antibiotic, Recarbrio® (Imipenem/Cilastatin/Relebactam), in China, which is indicated for treating infections caused by sensitive Gram-negative bacteria in patients aged 18 and older [4] Capital Markets - Jingtai Holdings plans to acquire 90% of Shanghai Siwei Medical Technology for a total consideration of 250 million yuan, enhancing its capabilities in AI healthcare and drug development [6] - Yihe Jiaye has signed a strategic cooperation framework agreement with Shenzhen Hanyu Pharmaceutical and Shenzhen Hanyu Health Technology to develop a sleep health ecosystem through resource integration [7] Industry Developments - Kintor Pharmaceutical released preliminary clinical data for its CT0596 CAR-T cell injection targeting BCMA, currently under exploration for treating relapsed/refractory multiple myeloma [9] - Hanyu Pharmaceutical has agreed to collaborate with Shenzhen Carbon Cloud Peptide Technology on the development of a novel peptide drug targeting GLP-1R/GIPR/GCGR, which currently has no similar products approved for market [10] - Eli Lilly's tirzepatide has shown superior weight loss efficacy compared to Novo Nordisk's semaglutide in a head-to-head clinical trial, potentially reshaping the obesity treatment market [11]

Investment Rating - The report does not explicitly state an investment rating for the medical device industry. Core Insights - The Chinese medical device industry is experiencing rapid growth driven by policy reforms and increasing domestic demand, with a significant rise in the number of production enterprises from 16,356 in 2018 to 36,675 in 2023, reflecting a compound annual growth rate (CAGR) of 17.5% [5][13]. - The market for high-value medical devices (Class III) is expanding, with a notable increase in manufacturers, which grew by 15.5% from 2022 to 2023 [13]. - The medical device market in China is projected to grow from CNY 528.4 billion in 2018 to CNY 1,502.4 billion by 2028, with a CAGR of 14.9% [31]. Summary by Sections Chapter 1: Overview of the Chinese Medical Device Industry - The classification and layout of the medical device industry in China highlight the importance of production capacity and the number of devices held by medical institutions as key indicators of healthcare quality [4][6]. - Recent policy changes have lowered entry barriers for domestic manufacturers and improved the feasibility of remote consultations, enhancing service quality and efficiency [6][9]. Chapter 2: Current Development of the Chinese Medical Device Industry - The industry has undergone a period of contraction followed by recovery and stabilization, with significant regulatory changes promoting innovation and improving the quality and safety of domestic products [16][18]. - The number of registered medical devices has increased, with a shift towards innovative products, particularly in high-value categories [20][24]. Chapter 3: Analysis of the Overseas Expansion of Chinese Medical Devices - The export value of Chinese medical devices surged from CNY 162.2 billion in 2018 to CNY 807.6 billion in 2020, reflecting a CAGR of 123.1% [37]. - In 2023, the export of medical consumables surpassed diagnostic equipment, accounting for 44.9% of total exports, driven by competitive pricing and innovation [37][38]. Chapter 4: Frontier Development Trends in the Chinese Medical Device Industry - The integration of AI in medical devices is gaining momentum, with the Chinese government supporting digital healthcare initiatives to enhance local capabilities and reduce the gap with international standards [46][49]. - The report indicates a growing trend in the adoption of AI technologies in imaging devices, with a significant portion of approvals for AI medical devices in the imaging sector [51].

Core Viewpoint - The announcement of a new executive order by Trump to reduce prescription drug prices in the U.S. has led to a significant decline in the innovation drug sector in Hong Kong and A-shares, with ETFs dropping over 4% [1][2] Group 1: Market Reaction - The Hang Seng Innovation Drug ETF, Hong Kong Stock Connect Innovation Drug ETF, and other related ETFs experienced declines exceeding 4% following the news [1] - The executive order is expected to lower drug prices by 30% to 80%, which may lead to a global price increase to maintain balance [2] Group 2: Industry Analysis - The pharmaceutical sector's attention has increased, with A-share pharmaceutical fund holdings at 8.53% in Q1 2025, remaining stable, while non-pharmaceutical fund holdings decreased slightly [3] - The top three segments in pharmaceutical stock holdings are chemical preparations (41.81%), medical research outsourcing (17.02%), and medical devices (11.95%) [3] Group 3: Future Outlook - The focus on innovation and self-sufficiency is emphasized, with a recommendation to pay attention to innovative drugs and improving fundamentals in the drug supply chain [4] - The pharmaceutical sector is expected to stabilize and grow, driven by innovation and increasing clinical demand due to aging populations [4]